Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGINALE post-trial passive follow-up study
NL-OMON38811Active, not recruiting
- Sponsor
- Population Health Research Institute
- Start
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, double-blind trial of insulin glargine and omega-3-acid triglycerides in impaired fasting glucose (IFG), prediabetes and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Population Health Research Institute. Primary endpoints: Cardiovascular morbidity and mortality and Cardiovascular mortality. Started Jun 2013; status: active, not recruiting.
02
Drugs
insulin glargineomega-3-acid triglycerides
03
Conditions
impaired fasting glucose (IFG)prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON38811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38811.